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(ILD) like event was reported in 5 pts (4.6%). Two of these pts had 
fatal outcome. 
Conclusions: The present analysis demonstrates good efﬁcacy and 
shows the acceptable safety proﬁle of erlotinib in Japanese patients 
with previously treated advanced NSCLC. On the basis of integrated 
survival data, the results of Cox regression analysis for prognostic fac-
tors will be presented.
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Background: Lung cancer in the female population is a growing 
sanitary problem. Gender-related differences in susceptibility, patho-
genesis and possible cure for this disease are interesting ﬁelds of basic 
and clinical investigation. Female sex, adenocarcinoma histology, non 
smoking history represent clinical features correlated with response 
to EGFR-TKIs. The use of these molecules in patients selected on a 
“clinical enrichment” basis are warranted. 
Patients and Methods: The mutational status of EGFR (exons from 
18 to 21) and K-ras (exon 1) is routinely evaluated in patients with 
adenocarcinoma of the lung referred to our Institution. From January 
2006 30 women with advanced NSCLC were observed: median age 60 
yrs (37-80); smokers=12 pts (40%); non smokers=18 (60%). Adenocar-
cinoma= 22 pts (73.3%); BAC =6 (20%); adenocarcinoma with BAC 
features= 2 (6.7%). Fifteen pts (50%) had stage IV disease at diagnosis 
and 5 of them (33.3%) showed brain metastases. 
Results: 9/30 (30%) EGFR mutations were detected: 5 in exon 19; 2 
in exon 21; 2 in exon 20. 3/30 (10%) K-ras mutations were noted. 11 
patients received TKIs (Geﬁtinib 250 mg/die or Erlotinib 150 mg/die 
orally) as second-line therapy for at least 2 months and were evaluable 
for activity: 5 PR (45%) and 6 PD (55%) were observed. All respond-
ing patients were non smokers; 3 had mutation in exon 19, 1 in exon 21 
and 1 had Wild Type EGFR. All were WT K-ras. Among patients with 
PD: 1 had tumor with mutation in exon 21, 2 had tumors with K-ras 
mutation and 3 WT EGFR. Median progression-free survival was 5 
months (range 2-14+ months); median overall survival was 27 months 
(range 8-108 months).
Conclusions: In our “clinically enriched” population (women with 
adenocarcinoma) we can observed that: 1) 60% of patients were non 
smokers; 2) 17% had brain metastases at diagnosis; 3) the frequence 
of EGFR mutations is 30% (higher than that reported in caucasian 
non selected series); 4) the most frequent EGFR mutation was in exon 
19. In patients receiving second-line TKIs response rate was 45%; 
all responding patients were non smokers and 4/5 (80%) had tumors 
with EGFR mutations. The study is ongoing. Updated results will be 
presented at the meeting. 
Supported by AIDA CP: Italian Association of Women against Lung 
Cancer. 
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Background: Erlotinib and geﬁtinib are epidermal growth factor 
receptor (EGFR) tyrosine kinase inhibitors (TKIs). They have the same 
mechanism of action and very similar side effect proﬁle. Erlotinib is 
the only EGFR TKI being approved for salvage treatment of patients 
with advanced stage of non-small cell lung cancer (NSCLC). Pharma-
codynamic studies showed that erlotinib has higher Cmax and AUC, 
but shorter half life compared to geﬁnitib. We observed the efﬁcacy and 
toxicity proﬁle of erlotinib in the treatment of patients with NSCLC 
who had failed previous geﬁtinib treatment.
Methods: Eligibilities were histologically and/or cytologically proven 
NSCLC Erlotinib 150 mg was orally administered daily. We evaluated 
tumor response, including objective response rate (ORR), disease con-
trol rate (DCR), time-to-progression (TTP), toxicity proﬁle and patient 
median survival (MS).
Results: From December 2005 to December 2006, twenty-ﬁve patients 
who had failed prior geﬁtinib treatment were included: M/F 13/12; 
median age 67.5; stage IIIB and IV, ECOG performance status 0-3. 
The ORR was 8.3%, DCR 37%, MS:8.9months. TTP:10.7months. In 
the geﬁtinib refractory group (N=5), disease control rate is 0%; in the 
geﬁtinib resistance group (N=20), disease control rate is 45%. Erlotinib 
showed slightly increase in skin toxicity but manageable.
Conclusions: Our data revealed that erlotinib demonstrated a minimal 
response in patients who failed prior geﬁnitib and tolerable toxicity. 
Erlotinib may be considered as an option of salvage treatments in pa-
tients who have poor performance, signiﬁcant co-morbidities and who 
hesitate to have conventional chemotherapy.
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Background: Several retrospective analyses reported that somatic 
activating mutations in the EGFR tyrosine kinase domain underlie 
responsiveness to geﬁtinib. In this multicenter study, we have prospec-
tively assessed whether these speciﬁc mutations in EGFR gene affect 
the clinical outcomes of NSCLC patients treated with geﬁtinib. 
Method: Chemotherapy-naive or recurrent patients within two 
regimens, stage IIIB/IV NSCLC that harbored EGFR mutations were 
